Thermo Fisher Scientific, the world leader in serving science, has announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors.
Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified patient lives across the US healthcare system.
The datasets will provide deep insights into disease prevalence, treatment patterns and provider activity, further strengthening the clinical research business’ data and AI driven services across trial feasibility and optimization, recruitment and real-world evidence generation.
The agreement also provides access to a marketplace of more than 70 curated data sources, including electronic medical records, laboratory results and other specialty datasets. With streamlined access to longitudinal claims and linked datasets, the business can deliver more precise site selection strategies and improved startup timelines.
In addition, the collaboration enhances the business’ real-world evidence and health economics and outcomes research (HEOR) offerings across PPD™ CorEvitas™ Clinical Registries and PPD™ Evidera™ solutions, enabling faster analytics and expanded registry-linked claims capabilities.
The collaboration will allow the PPD™ clinical research business to gain increased flexibility to better position the business to deliver differentiated value, while maintaining rigorous privacy protections and data governance standards.
It also builds on Thermo Fisher’s continued investment in digital innovation to support smarter, more efficient clinical development and improved patient outcomes.
